Clinical efficacy of treatment with low-dose flutamide in maximum androgen blockade therapy

To prevent treatment withdrawal due to flutamide-induced liver dysfunction, we performed maximum androgen blockade (MAB) therapy by combining a luteinizing hormone-releasing hormone agonist or orchiectomy with low-dose flutamide (125 mg x 2/day) in patients with prostate cancer. In this study, the e...

Ausführliche Beschreibung

Bibliographische Detailangaben
Veröffentlicht in:Hinyokika kiyo. Acta urologica Japonica. - 1962. - 47(2001), 4 vom: 24. Apr., Seite 251-5
1. Verfasser: Shimizu, K (VerfasserIn)
Weitere Verfasser: Kiyohara, H, Nakayama, J, Fujii, T, Hosomi, M
Format: Aufsatz
Sprache:Japanese
Veröffentlicht: 2001
Zugriff auf das übergeordnete Werk:Hinyokika kiyo. Acta urologica Japonica
Schlagworte:Journal Article Androgen Antagonists Gonadotropin-Releasing Hormone 33515-09-2 Flutamide 76W6J0943E Prostate-Specific Antigen EC 3.4.21.77
Beschreibung
Zusammenfassung:To prevent treatment withdrawal due to flutamide-induced liver dysfunction, we performed maximum androgen blockade (MAB) therapy by combining a luteinizing hormone-releasing hormone agonist or orchiectomy with low-dose flutamide (125 mg x 2/day) in patients with prostate cancer. In this study, the efficacy, adverse effects such as hepatotoxicity, and compliance were compared retrospectively between 35 patients who received low-dose flutamide therapy (1995-1999) and 27 patients who received flutamide at its ordinary dose (125 mg x 3/day). No significant difference was observed in the response rate (> or = PR) as determined from the prostate-specific antigen parameter (p = 0.6211) or the incidence of hepatotoxicity based on the aspartate aminotransferase and alanine aminotransferase levels. However, flutamide withdrawal due to liver dysfunction was less frequent in the low-dose group (2.9%) than in the ordinary dose group (18.5%) (p = 0.0386). MAB therapy using low-dose flutamide is expected to prevent the reduction in the compliance due to side effects and to improve the long-term prognosis in patients with prostate cancer, who are mostly elderly individuals
Beschreibung:Date Completed 12.07.2001
Date Revised 24.11.2016
published: Print
Citation Status MEDLINE
ISSN:0018-1994